Logout Login Cart iconShop Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "中国股市 2026年1月2月3月 上证指数 月线 收盘数据 历史行情"

Looking for quality documents?
external link icon
Repligen Reports Second Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance
– Reports second quarter revenues of $159.2 million as reported, and base business revenues of $157.1 million, down 9% year-over-year – Adjusts full year revenue guidance to range of $635-$665 million WALTHAM, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter (Q2) and first half (H1) of 2023, covering the three- and six-month fiscal periods ended June 30, 2023. Provided in this press release are financial performance highlights, updates to our guidance for the year 2023 and access information for today’s webcast and conference call. Tony J. Hunt, President and Chief Executive Officer of Repligen said, “2023 continues to be a challenging year for bioprocessing. Our base business performance in the second quarter and first half of 2023 held up reasonably well with base revenues down 9% and 3% respectively. Our Analytics, Proteins
external link icon
Repligen to Report Third Quarter 2017 Financial Results
WALTHAM, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report third quarter of 2017 financial results on Thursday, November 9, 2017.  The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EST to discuss business updates and financial results for the 3-month and 9-month reporting periods ended September 30, 2017. The conference call will be accessible by dialing toll-free (800) 708-4539 for domestic callers and (847) 619-6396 for international callers. Dial-in participants must provide the passcode 45935245. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (888) 843-7419 for domestic callers and (630) 652-3042 for international callers. Replay listeners must provide the passcode
external link icon
Repligen to Report Second Quarter 2017 Financial Results
WALTHAM, Mass., July 27, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report second quarter of 2017 financial results on Thursday, August 3, 2017.  The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the reporting periods ended June 30, 2017.
The conference call will be accessible by dialing toll-free (844) 835-7432 for domestic callers and (404) 537-3372 for international callers. Dial-in participants must provide the passcode 62585996. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Replay listeners must provide the passcode 62585996. About
external link icon
Repligen to Report Third Quarter 2016 Financial Results
WALTHAM, Mass., Oct. 20, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report third quarter 2016 financial results on Thursday, November 3, 2016. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the reporting period ended September 30, 2016. The conference call will be accessible by dialing toll-free (844) 835-7432 for domestic callers and (404) 537-3372 for international callers. Dial-in participants must provide the passcode 2006569. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Replay listeners must provide the passcode 2006569. About Repligen
external link icon
Repligen Receives Complete Response Letter from FDA for RG1068 NDA
Repligen Corporation (NASDAQ:RGEN) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food & Drug Administration (FDA) regarding the Company’s New Drug Application (NDA) for RG1068 (synthetic human secretin). RG1068 was evaluated in a Phase 3 study to improve detection of pancreatic duct abnormalities in combination with MRI in patients with known or suspected pancreatitis. The CRL indicates that the FDA has completed its review of the RG1068 NDA and has determined that additional clinical efficacy and safety trial data will be required to support potential approval of the NDA. There were no specific safety concerns cited in the CRL, although safety will continue to be monitored in conjunction with any future clinical trial. No deficiencies were cited in the CRL with respect to the manufacturing, pharmacology or toxicology sections of the NDA. “We will continue to engage in dialogue with the FDA to determine the design and scope of a clinical
news icon
Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference
Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the 43rd Annual J.P. Morgan Healthcare Conference, being held January 13 – 16 in San Francisco. Olivier Loeillot, President and Chief Executive Officer, will present an overview of the company on Tuesday, January 14 at 1:30 p.m. PT.
external link icon
Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the 43 rd Annual J.P. Morgan Healthcare Conference, being held January 13 – 16 in San Francisco. Olivier Loeillot, President and Chief Executive Officer, will present an overview of the company on Tuesday, January 14 at 1:30 p.m. PT. A live webcast of the conference presentation will be accessible through Repligen’s  Investor Relations website at www.repligen.com , and will be available for replay for a limited period of time following the event. About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily
external link icon
Repligen Corporation to Present at Barclays Global Healthcare Conference
WALTHAM, Mass., March 03, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the Barclays Global Healthcare Conference being held March 9-11. Jon Snodgres, Chief Financial Officer, will participate in a fireside chat on Wednesday, March 10, at 1:50 p.m. EST. A live webcast of the discussion will be accessible through the  Investor Relations section of the Company’s website, and will be available for replay for a limited period of time following the conference event. About Repligen Corporation Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. Our primary customers are biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our
external link icon
Repligen to Participate in 13th Annual Craig-Hallum Institutional Investor Conference
WALTHAM, Mass., May 26, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a leading innovator and provider of high-value products to improve the process of manufacturing biologic drugs, today announced that it will participate in the 13 th Annual Craig-Hallum Institutional Investor Conference being held on June 1 in Minneapolis, MN. This conference provides institutional investors the opportunity to meet with Company management and does not include a formal presentation. Repligen’s most recent investor presentation will be accessible through the Investor Events section of Company’s website.
About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a life sciences company focused on the development and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are the leading manufacturer of Protein A
publications icon
Continuous Bioprocessing: Industry Best Practices Publication
E-book Volume 2 February 2018 Compiled by John Bonham-Carter, Repligen Chapters Introduction to Continuous Bioprocessing: Current Status and Trends Eric S. Langer, BioPlan Associates, Inc. and and Ronald A. Rader How to Develop a Perfusion Process Véronique Chotteau, Royal Institute of Technology (KTH) Strategies for development of perfusion media Delia Lyons, MilliporeSigma and Jochen Sieck, Merck KGaA Perfusion Application in Mobius® Single-use Bioreactors Michael Cunningham and Douglas Rank, MIlliporeSigma XCell ATF® Perfusion Technology Delivers High Throughput: Efficient Seed Train Process with Improved Fed-Batch Production Output W. Roy Lin, Shashi Kudugunti, Mario Sinani, Tim Erlandson and Dr. James Rusche, Repligen Product Quality Considerations of Perfusion Processes Thomas Villiger, Daniel Karst and Massimo Morbidelli, ETH Zurich Impurity Monitoring as Novel PAT Tool for Continuous Biopharmaceutical Processes Vignesh Rajamanickam, Dr. Patrick Sagmeister, Oliver Spadiut, and Christoph Herwig, TU Wien Austria Insect Cells and ATF Willem Adriaan (Wian) de Jongh, PhD, ExpreS2ion Biotechnologies Scale up and Technology Transfer in a Continuous Processing Environment Sadettin S. Ozturk, Ph.D., Massbiologics Continuous Multicolumn Chromatography Processes Marc Bisschops, Pall Corporation Impact of Single‑use Technology on Continuous Bioprocessing William G. Whitford, GE Healthcare Continuous Bioprocessing's Impact on Facility Design Morten Munk, NNE A/S